开发基于单一实体的治疗诊断一体化：具有增强细胞毒性的药物荧光纳米团簇。
Developing single-entity theranostic: drug-based fluorescent nanoclusters with augmented cytotoxicity.
机构信息
Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India.
Department of Biosciences & Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, India.
出版信息
Nanomedicine (Lond). 2018 Feb;13(3):283-295. doi: 10.2217/nnm-2017-0275. Epub 2018 Jan 18.
AIM
To develop methotrexate (MTX) templated luminescent gold nanoclusters (NCs) as a single unit nanotheranostic for cancer therapy and to assess its potential as an alternative to the parent drug, for drug delivery vehicles (DDVs).
METHODS
Theranostics were synthesized and extensively characterized. The stability of the theranostic and its bioimaging aptitude were evaluated. The antiproliferative propensity of the theranostic was gauged with cell viability assays and was supplemented with cytometry-based assays. Feasibility of delivering the MTX NCs instead of parent drug on a DDV was also checked.
RESULTS
MTX NCs displayed remarkable physical characteristics and augmented cytotoxicity with a robust stability in phosphate-buffered saline and serum. MTX NCs also demonstrated their amenability to being loaded on a DDV (chitosan folic acid nanoparticles) while retaining their physical and cytotoxic profile.
CONCLUSION
Generation of next level drug-based theranostics with the potential of replacing the free drug in drug delivery platforms.
目的
开发甲氨蝶呤（MTX）模板化的发光金纳米簇（NCs）作为癌症治疗的单一单元纳米治疗药物，并评估其作为亲代药物的替代物用于药物传递载体（DDV）的潜力。
方法
合成并广泛表征了治疗药物。评估了治疗药物的稳定性及其生物成像能力。通过细胞活力测定法评估了治疗药物的抗增殖倾向，并辅以基于细胞术的测定法。还检查了用 MTX NCs 代替 DDV 上的亲代药物的可行性。
结果
MTX NCs 表现出显著的物理特性，并在磷酸盐缓冲盐水和血清中具有增强的细胞毒性和强大的稳定性。MTX NCs 还表现出易于被加载到 DDV（壳聚糖叶酸纳米粒子）上，同时保持其物理和细胞毒性特征。
结论
生成具有在药物传递平台中替代游离药物潜力的下一代基于药物的治疗药物。
Zotero 插件